Product Description
Mechanisms of Action: HCV-NS3/4A Inhibitor
Novel Mechanism: No
Modality: Small Molecule
Route of Administration: Oral
FDA Designation: *
Approval Status: Not Approved
Approved Countries: None
Approved Indications: None
Company: Dongguan HEC TaiGen Biopharmaceuticals
Company Location: Asia Pacific
Company Founding Year: None
Additional Commercial Interests: None
Clinical Description
Countries in Clinic:
Active Clinical Trial Count:
Recent & Upcoming Milestones
Highest Development Phases
Phase 3: Liver Cirrhosis
Phase 2: Liver Cirrhosis|Hepatitis C, Chronic|Hepatitis A
Phase 1: Healthy Volunteers|Hepatitis C, Chronic|Cross Infection
Trial ID |
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
Latest Trial Update Date |
Data Updated |
|---|---|---|---|---|---|---|---|---|
NCT03610880 |
TGDAG-C-1 | P1 |
Completed |
Healthy Volunteers |
2018-02-05 |
2019-03-22 |
Treatments |
|
NCT03610867 |
TG-2349-C-01 | P1 |
Completed |
Healthy Volunteers |
2017-08-31 |
2019-03-22 |
Treatments |
|
NCT02108418 |
TG-2349-02 | P1 |
Completed |
Cross Infection|Hepatitis C, Chronic |
2014-06-01 |
2019-03-20 |
Treatments |
|
NCT01523990 |
TG-2349-01 | P1 |
Completed |
Hepatitis C, Chronic |
2012-04-01 |
2019-03-19 |
||
CTR20190877 |
CTR20190877 | P1 |
Not yet recruiting |
Hepatitis C, Chronic |
None |
2025-04-29 |
Patient Enrollment|Treatments |
|
NCT03593447 |
TGDAG-C-2 | P2 |
Completed |
Liver Cirrhosis |
2019-04-23 |
2021-02-19 |
Patient Enrollment|Primary Completion Date|Primary Endpoints|Study Completion Date|Treatments|Trial Status |
|
NCT02340962 |
TG-2349-03 | P2 |
Completed |
Hepatitis C, Chronic|Hepatitis A |
2016-08-12 |
2019-03-20 |
Treatments |
|
NCT04155515 |
TGDAG-C-3 | P3 |
Completed |
Liver Cirrhosis |
2020-08-11 |
40% |
2021-02-04 |
Patient Enrollment|Primary Completion Date|Primary Endpoints|Study Completion Date|Treatments|Trial Status |
Recent News Events
Date |
Type |
Title |
|---|---|---|
|
08/05/2021 |
News Article |
Hepatitis C Drug Pipeline Market Research Report 2021 - ResearchAndMarkets.com |
|
03/26/2021 |
News Article |
2021 Hepatitis C Pipeline Insights - Featuring HEC Pharm, Atea Pharmaceuticals & AllaChem Among Others - ResearchAndMarkets.com |
|
11/09/2020 |
News Article |
TaiGen Partners with GPCR to develop Burixafor & Taigexyn(R) |
|
11/01/2020 |
News Article |
TaiGen Announces FDA Approval of IND for Its Flu Antiviral TG-1000 |